Owned by the Association for International Promotion & Study in Tumors (APSIT)
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers
Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm a...
Citation: Journal of Experimental & Clinical Cancer Research 2019 38:499